Table I-Concentration of Cocaine in Nine Species of Erythroxylum as Determined by GLC

Species	Collector	Specimen tor Number Locality		Herbar- Collection ium ^a Date		Cocaine [,] %	
E. campestre A. St. Hil. E. citrifolium A. St. Hil. E. deciduum A. St. Hil. E. deciduum A. St. Hil. E. novogranatense (Morris) Hioron	P. Dusen W. H. Lewis <i>et al.</i> L. O. Williams L. B. Smith & Klein R. E. Schultes	16421 254 7424 7452 —	Brazil Panama Brazil Brazil Cuba	MO MO MO NY NY	? 1966 1945 1956 1955	0.00014 n.d. n.d. 0.00080 0.00882	
E. novogranatense (Morris)	Br. Daniel	15584	Colombia	OA	1 9 61	0.00216	
E. panamense Turcz. E. panamense Turcz. E. pelleterianum A. St. Hil. E. rufum Cav. E. rufum Cav. E. coca Lam. ^c E. coca Lam.	T. B. Croat T. B. Croat Y. Mexia Riedel E. L. Ekman R. A. Howard J. A. Duke	5519 4879 4364 390 11609 12247 —	Canal Zone Canal Zone Brazil Brazil Santo Domingo Dominican Republic	MO MO MO AA AA —	1968 1968 1930 ? 1929 1950 1974 <1930	0.00121 0.00141 0.00123 0.00008 n.d. n.d. 0.53 0.03	

 a MO = Missouri Botanical Gardens, NY = New York Botanical Gardens, OA = Oaks Ames Economic Herbarium, Harvard University; and AA = Arnold Arboretum Herbarium, Harvard University. b Single leaves were analyzed, with data being expressed as the mean percent of two determinations; n.d. = co-caine not detected. e Leaf material from a 2-year-old living plant was collected and analyzed within 48 br.

A sample of E coca leaf analyzed within 2 days from the time of removal from the living plant contained 0.53% of cocaine, whereas a dried and stored sample at least 44 years old still contained 0.03% cocaine.

Studies are currently in progress to determine the decomposition rate of cocaine in stored E. coca leaves, as well as the natural variability of this alkaloid in various populations of E. coca.

REFERENCES

(1) A. Engler, "Syllabus der Pflanzenfamilien," vol. II, Gebrüder Borntraeger, Berlin, Germany, 1964.

(2) J. J. Willaman and B. G. Schubert, "Alkaloid-bearing Plants and Their Contained Alkaloids," Tech. Bull. No. 1234, Agricultural Research Service, U. S. Department of Agriculture, Washington, D.C., 1961.

(3) J. J. Willaman and H.-L. Li, *Lloydia*, 33 (3A), 1(1970).

(4) "The Wealth of India," vol. III (D-E), Council of Scientific & Industrial Research, New Delhi, India, 1952, p. 200.

(5) B. L. W. Chu and E. S. Mika, J. Pharm. Sci., 59, 1508(1970).

ACKNOWLEDGMENTS AND ADDRESSES

Received April 2, 1974, from the *Department of Pharmacognosy and Pharmacology, College of Pharmacy, University of Illinois at the Medical Center, Chicago, IL 60612, and the [‡]Plant Taxonomy Laboratory and the [§]Pesticide Action Laboratory of the Agricultural Environmental Quality Institute (AEQI), U.S. Department of Agriculture, Agricultural Research Service, Northeastern Region, Agricultural Research Center, Bethesda, MD 20705 Accepted for publication May 21, 1974.

The authors thank Professor H. H. S. Fong for helpful suggestions and discussions.

* To whom inquiries should be directed.

Synthesis and Anti-Inflammatory Evaluation of 2-(Substituted Amino)quinolizinium Bromides

ROBERT J. ALAIMO × and MARVIN M. GOLDENBERG

Abstract \Box The synthesis and anti-inflammatory evaluation of a number of 2-(substituted amino)quinolizinium bromides, including some previously unreported analogs, are described. The more active compounds in inhibiting carrageenin-induced edema formation are those containing a *p*-alkoxyanilino group in the 2-position of the quinolizinium ring.

Previously, the synthesis and antiparasitic screening of a series of 2-(substituted amino)quinolizinium bromides were reported (1). Many of these compounds (III-XL) exhibited a significant degree of anthelmintic activity. The primary anti-inflammatory evaluation of this series of compounds, including some previously unpublished analogs, is reported Keyphrases □ Quinolizinium bromides, 2-(substituted amino) synthesis and anti-inflammatory evaluation □ Aminoquinolizinium bromides (2-substituted)—synthesis and anti-inflammatory evaluation □ Anti-inflammatory activity—evaluation of 38 2-(substituted amino)quinolizinium bromides

herein. Compounds III-XL, when examined in the carrageenin-induced rat paw edema assay, inhibited edema formation as much as 76%.

The previously reported (1) synthesis involves the reaction of an appropriately substituted amine with either of the two intermediates, 2-bromoquinolizinium bromide (I) or 2-bromo-6-methylquinolizinium



Table I-Anti-Inflammatory Evaluation of Certain Quinolizinium Bromides

Compound	\mathbf{R}_1	\mathbf{R}_2	Inhibition of Edema Formation ^a , %
III IV V VI VII VIII IX X X XII XIII XI	Н Н Н Н Н Н Н Н Н Н Н Н Н Н Н Н Н Н Н	$\begin{array}{c} C_6H_5 \\ 4\text{-BrC}_6H_4 \\ 4\text{-}C_6H_5N = N - C_6H_4 \\ 4\text{-}(CH_3)_2NC_6H_4 \\ 4\text{-}(CH_3)_2NC_6H_4 \\ 4\text{-}(CH_3)_2NC_6H_4 \\ 4\text{-}(CH_3)_2CHOC_6H_4 \\ 4\text{-}(CH_3)_2CHOC_6H_4 \\ 4\text{-}(CH_3)_2CHCH_2OC_6H_4 \\ 4\text{-}(CH_3)_2CHCH_2OC_6H_4 \\ 4\text{-}CH_3(CH_2)_3OC_6H_4 \\ 4\text{-}CH_4(CH_2)_3OC_6H_4 \\ 4\text{-}CH_2 = CHCH_2OC_6H_4 \\ 4\text{-}C_6H_5OC_6H_4 \end{array}$	5926396258446841762644176731
XVII	Н	4- OC ₆ H ₁	67
XVIII XIX XX XXI XXII XXIII XXIII XXIV XXVI XXVII XXVIII XXVIII XXVIII XXXIX XXX XX	H H H H H H H H H H H H H H CH ₂ CH ₂ CH ₂ CH ₂	$\begin{array}{c} 3\text{-}CH_3CHOHC_6H_4\\ 2\text{-}CH_3OC_6H_4\\ 2\text{-}C_2H_5OC_6H_4\\ 3,4\text{-}(CH_3)_2C_6H_3\\ 3,4\text{-}(CH_3O)_2C_6H_3\\ 2,4\text{-}(CH_3O)_2C_6H_3\\ 2,4\text{-}(CH_3O)_2C_6H_3\\ 2\text{-}CH_3\text{-}-4\text{-}CH_3OC_6H_2\\ 2,4,6\text{-}(CH_3O)_2\text{-}-5\text{-}CIC_6H_2\\ 2,4\text{-}(CH_3O)_2\text{-}-4\text{-}CIC_6H_2\\ 2,5\text{-}(CH_3O)_2\text{-}-4\text{-}CIC_6H_2\\ 2,5\text{-}(CH_3O)_2C_6H_3\\ 2\text{-}CH_3O\text{-}5\text{-}CH_3C_6H_3\\ 4\text{-}CH_2CHOHCH_2\\ 4\text{-}OCH_2CH_2\\ CH_2CH_2OCH_2CH_2\\ 2\text{-}CH_2OCH_2CH_2\\ 2\text{-}CH_2CH_2OCH_2CH_2\\ 2\text{-}CH_2CH_2OCH_2CH_2\\ 2\text{-}CH_2CH_2OCH_2CH_2\\ 2\text{-}CH_2CH_2CH_2\\ 2\text{-}CH_2CH_2OCH_2CH_2\\ 2\text{-}CH_2CH_2CH_2\\ 2\text{-}CH_2CH_2CH_2\\ 2\text{-}CH_2CH_2CH_2\\ 2\text{-}CH_2CH_2CH_2\\ 2\text{-}CH_2CH_2CH_2\\ 2\text{-}CH_2CH_2\\ 2\text{-}CH_2CH_2\\ 2\text{-}CH_2CH_2\\ 2\text{-}CH_2CH_2\\ 2\text{-}CH_2\\ 2\text{-}CH_2CH_2\\ 2\text{-}CH_2\\ 2-$	$\begin{array}{c} 0\\ 9\\ 21\\ 50\\ 8\\ 29\\ 46\\ 19\\ 0\\ 2\\ 34\\ 51\\ 41\\ 0\\ 3\end{array}$
XXXIII	$\rm NH_2$	C ₂ H ₅ -CH ₂ CH ₂	22
XXXIV XXXV XXXVI XXXVII XXXVIII XXXIX XL XLI	H H H H NH2 CH2==CHCH2 Phenylbutazone ^b	$\begin{array}{c} 3\text{-}{\bf CF}_3{\bf C}_6{\bf H}_4 \\ 4\text{-}{\bf CH}_3{\bf OC}_6{\bf H}_4 \\ 4\text{-}{\bf C}_2{\bf H}_3{\bf OC}_6{\bf H}_4 \\ 4\text{-}{\bf CH}_3{\bf SC}_6{\bf H}_4 \\ 2,4\text{-}({\bf CH}_3{\bf O})_2{\bf C}_6{\bf H}_3 \\ {\bf HOC}{\bf H}_2{\bf CH}_2 \\ {\bf CH}_2 = {\bf CHCH}_2 \end{array}$	53 12 44 9 22 34 34 59

^a Compared to control (nondrug treated) hindpaw 4 hr after carrageenin administration. Compounds administered at 300 mg/kg. ^b Phenylbutazone administered at 100 mg/kg.

bromide (II) (Scheme I).

The compounds were tested for anti-inflammatory activity according to the carrageenin method reported by Winter *et al.* (2). Each compound was suspended in distilled water by sonification and administered perorally, 300 mg/kg in three male Wistar rats, 1 hr prior to subplantar injection of 0.05 ml of a 1% solution of carrageenin¹ into the left hindfoot. The percentage reduction of edema formation (as



¹ Viscarin.

compared to a nondrug-treated control) in the rat hindpaw was recorded 4 hr after carrageenin administration. For comparison, the reference anti-inflammatory drug phenylbutazone (XLI) was tested (Table I).

The more active compounds exhibiting a high degree of reduction of the carrageenin-induced edema formation had a substituted anilino group in the 2position of the quinolizinium ring. The presence of the methyl group in the 6-position (XXXVI and XXXVIII) did not appear to alter the degree of antiinflammatory activity when compared with the corresponding demethyl compounds (VIII and XXIII).

Substitution on the anilino ring with alkoxy or dialkylamino groups in the 4-position resulted in the highest degree of anti-inflammatory activity (VI, VII, IX, XI, XV, and XVII), and the active quinolizinium compounds did not exhibit overt signs of toxicity, central depression, or lethality in doses that exerted marked anti-inflammatory activity.

I able II - maiy fical and I hysical Data for the Compound	Tε	ıble	II-A	nalytical	and	Physical	Data	for	New	Compounds
---	----	------	------	-----------	-----	----------	------	-----	-----	-----------

	Melting Point	F Yield, %	Recrystallization Solvent		Analysis, %		
Compound				Formula	Calc.	Found	
v	239–240°	90	C ₂ H ₅ OH	$C_{21}H_{17}BrN_4$	C 62.23 H 4.23 Br 19.72	62.07 4.29 19.67	
XXX	166–168°	60	C_2H_5OH	$\mathrm{C_{12}H_{15}BrN_{2}O_{2}}$	$\begin{array}{c} C & 48.17 \\ H & 5.05 \\ Br & 26.71 \end{array}$	48.42 5.01 26.64	
XXXIX	209 –210°	92	C ₂ H ₆ OH	C ₁₂ H ₁₆ BrN ₃ O	C 48.33 H 5.41 Br 26.80	$\begin{array}{r} 23.01\\ 48.48\\ 5.28\\ 26.81\end{array}$	

EXPERIMENTAL²

 $2 \cdot (m \cdot \text{Trifluoromethylanilino})$ quinolizinium bromide (XXXIV) was prepared as follows. To a solution of 2-bromoquinolizinium bromide (I) (1) (45 g, 0.15 mole) in ethanol (600 ml) was added *m*-trifluoromethylaniline (50 g, 0.30 mole). The stirred mixture was boiled under reflux for 5 hr, then treated with charcoal, and filtered. The product was precipitated from the filtrate by the addition of anhydrous ether.

The crude product weighed 42 g (76%). Recrystallization from isopropanol-ether provided analytically pure material, mp 229-230°.

Anal.—Calc. for $C_{10}H_{12}BrF_3N_2$: C, 52.03; H, 3.28; N, 7.59. Found: C, 51.96; H, 3.25; N, 7.61.

All other 2-(substituted amino)quinolizinium bromides were prepared similarly. Compounds V, XXX, XXXIV, and XXXIX

² Melting points were determined in open capillary tubes using a Mel-Temp melting-point apparatus and are uncorrected. have not been reported previously; the analytical and physical data for V, XXX, and XXXIX are shown in Table II. Analytical and physical data for all other compounds (Table I) were reported previously (1).

REFERENCES

(1) R. J. Alaimo, C. J. Hatton, and M. K. Eckman, J. Med. Chem., 13, 554(1970).

(2) C. A. Winter, E. A. Risley, and G. V. Nuss, Proc. Soc. Exp. Biol. Med., 111, 544(1962).

ACKNOWLEDGMENTS AND ADDRESSES

Received June 17, 1974, from the Chemistry Division and Pharmacometrics Division, Norwich Pharmacal Company, Division of Morton-Norwich Products, Inc., Norwich, NY 13815

* To whom inquiries should be directed.

Halothane Uptake by Coacervate Systems

W. F. STANASZEK *x, R. S. LEVINSON *, and B. ECANOW ‡

Abstract □ Two aggregated coacervae systems (acacia-gelatin and gelatin-benzalkonium chloride) were analyzed for gas sorption of halothane with a gas chromatograph, using a modified tonometer as an absorption chamber. Similar studies were performed on each system after the coacervate had been broken or "dissolved." Differences in absorption or solubilizing effect between coacervates and dissolved coacervates were noted. A significant halothane gas uptake was observed in the highly structured coacervate system.

Keyphrases □ Halothane—uptake by acacia-gelatin and gelatinbenzalkonium chloride aggregated coacervate systems, uptake compared to broken coacervate systems □ Coacervate systems halothane uptake by acacia-gelatin and gelatin-benzalkonium chloride systems and similar broken systems □ Acacia-gelatin coacervate system—halothane uptake, compared to similar broken system □ Gelatin-benzalkonium chloride system—halothane uptake, compared to similar broken system

The importance of solvent abilities in structured systems as well as a renewed interest in liquid crystalline states suggested that it would be of value to investigate the solvent abilities of a coacervate in contrast to the solvent abilities of an analogous "broken" coacervate. Coacervates may be considered to be coagulated systems, while "dissolved" or broken coacervates can be considered noncoagulated systems. In this study, a unique ability of coacervate systems to attract and solubilize nonpolar gases in a polar medium is discussed.

The term coagulation, as used here, refers to a type of aggregate characterized by film-film bonded particulates. The term coacervation denotes the formation of a liquid precipitate by the mutual coagulation of hydrophilic colloids (1). The definition of coacervation has been more elaborately discussed (2) as a phenomenon of the separation of colloidal solutions into two or more immiscible liquid phases. The electrostatic and thermodynamic properties of a colloidal solution can be varied in such a way that the system separates into two amorphous liquid layers. One layer contains most of the colloid (the coacervate), while the second layer is colloid poor (the equilibrium liquid). The coacervate appears in the form of

Accepted for publication July 25, 1974.